Acorda Therapeutics Alpha and Beta Analysis
| ACORDelisted Stock | USD 16.20 0.40 2.41% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Acorda Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Acorda Therapeutics over a specified time horizon. Remember, high Acorda Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Acorda Therapeutics' market risk premium analysis include:
Beta (1.10) | Alpha 1.19 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Acorda |
Acorda Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Acorda Therapeutics market risk premium is the additional return an investor will receive from holding Acorda Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Acorda Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Acorda Therapeutics' performance over market.| α | 1.19 | β | -1.1 |
Acorda Therapeutics Fundamentals Vs Peers
Comparing Acorda Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Acorda Therapeutics' direct or indirect competition across all of the common fundamentals between Acorda Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Acorda Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Acorda Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Acorda Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Acorda Therapeutics to competition |
| Fundamentals | Acorda Therapeutics | Peer Average |
| Return On Equity | -0.24 | -0.31 |
| Return On Asset | -0.0577 | -0.14 |
| Profit Margin | (2.15) % | (1.27) % |
| Operating Margin | 0.04 % | (5.51) % |
| Current Valuation | 161.45 M | 16.62 B |
| Shares Outstanding | 1.24 M | 571.82 M |
| Shares Owned By Insiders | 0.69 % | 10.09 % |
Acorda Therapeutics Opportunities
Acorda Therapeutics Return and Market Media
The Stock did not receive any noticable media coverage during the period. Price Growth (%) |
| Timeline |
About Acorda Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Acorda or other delisted stocks. Alpha measures the amount that position in Acorda Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Acorda Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Acorda Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Acorda Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Acorda Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Acorda Therapeutics. Please utilize our Beneish M Score to check the likelihood of Acorda Therapeutics' management manipulating its earnings.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with Acorda Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Consideration for investing in Acorda Stock
If you are still planning to invest in Acorda Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acorda Therapeutics' history and understand the potential risks before investing.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world |